The current situation of the levonorgestrel intrauterine system (LNG-IUS) in conservative treatment for patients with early-stage endometrial cancer and atypical hyperplasia

Xiaojun ChenJournal of Gynecologic Oncology 2019 · DOI · OpenAlex

Introduction

Endometrial cancer incidence is increasing globally, and it is frequently diagnosed in younger patients who wish to preserve their fertility. For these patients, the "gold standard" for conservative treatment has traditionally been high-dose oral progestins, such as medroxyprogesterone acetate (MPA) or megestrol acetate (MA). While effective, these systemic therapies carry significant drawbacks, including weight gain, headaches, and a heightened risk of life-threatening thromboembolic events. Furthermore, the requirement for strict daily adherence over several months often leads to compliance issues.

The levonorgestrel intrauterine system (LNG-IUS), a hormone-releasing device placed directly into the uterus, has emerged as a promising alternative. By delivering progestins locally, it aims to maximize therapeutic efficacy while minimizing systemic toxicity.

Advantages of Local Delivery

The primary benefit of the LNG-IUS is its localized mechanism of action. Because levonorgestrel is released directly into the uterine cavity, serum levels of the hormone remain significantly lower than those achieved with oral administration. This reduction in systemic exposure drastically lowers the risk of metabolic side effects and thrombosis.

Additionally, the LNG-IUS addresses the challenge of patient compliance. As a "one-time insertion" device, it eliminates the risk of missed doses, ensuring a continuous and stable hormonal environment for the suppression of endometrial lesions. There is also evidence suggesting that the persistent, localized release of progestin may be more effective at preventing recurrence once a complete response is achieved.

Clinical Outcomes and Efficacy

Recent clinical literature, including a retrospective study by Leone Roberti Maggiore et al. (2019), provides encouraging data regarding the efficacy of LNG-IUS. In their cohort of 48 patients, the complete response (CR) rate was 89.3% for atypical hyperplasia (EAH) and 81.3% for Grade 1 endometrioid endometrial cancer (EEC G1).

Broader systemic analyses further support these findings. A meta-analysis of 189 patients across 14 studies revealed a 90% regression rate for those treated with LNG-IUS, which was significantly higher than the 69% regression rate observed with traditional oral progestogens (p=0.03). While a 75% CR rate was noted for Grade 2 (EEC G2) patients, the sample size was too small (n=4) to draw definitive conclusions, necessitating extreme caution for more advanced subtypes.

Critical Considerations: Uterine Cavity Size

A significant finding in recent research is the impact of uterine anatomy on treatment success. The effectiveness of the LNG-IUS appears to be physically constrained by the size of the uterine cavity. In one study, non-responders had a median uterine diameter 1.3 cm larger than those who achieved a complete response. This suggests that in an enlarged cavity, the hormone may not reach the entire endometrial surface effectively, potentially leading to treatment failure.

Conclusion and Future Directions

While the LNG-IUS shows great promise as a fertility-sparing treatment, current evidence is largely limited to retrospective and observational studies with small cohorts. To establish the LNG-IUS as a standard of care, results from ongoing prospective clinical trials (such as NCT03241914, NCT03463252, and NCT03241888) are eagerly awaited.

Future research should also explore combination therapies—pairing the LNG-IUS with oral progestins or GnRH agonists—to optimize outcomes for patients with enlarged uterine cavities or higher-grade lesions. Refining patient selection criteria will be essential to ensuring that this localized therapy is used safely and effectively in the management of early-stage endometrial cancer.

Summary updated

BibTeX
@article{chen2019current,
  author = {Xiaojun Chen},
  title = {{The current situation of the levonorgestrel intrauterine system (LNG-IUS) in conservative treatment for patients with early-stage endometrial cancer and atypical hyperplasia}},
  journal = {Journal of Gynecologic Oncology},
  year = {2019},
  doi = {10.3802/jgo.2019.30.e79},
}
Figure